Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Core Insights - Silo Pharma is preparing to submit an investigational new drug (IND) application for its lead candidate SPC-15, aimed at treating PTSD and stress-induced anxiety, with preparations expected to commence before year-end 2025 [1][2][8] - The company has launched a digital assets treasury strategy to enhance capital resources and participate in cryptocurrency growth, combining staking for yield with a hedged overlay to mitigate volatility [2][4] Biopharmaceutical Platform - SPC-15 is advancing through final preparations for the IND submission, with positive results from a large animal safety study supporting its formulation [4][5] - The company is finalizing a drug-device study for the microchip-based nasal spray system used in SPC-15 delivery and has completed a GLP-compliant toxicology study, with data expected in early 2026 [5][8] - Silo is expanding its global intellectual property portfolio for SPC-15 technology, securing patents in the U.S., Australia, and Japan [5] Digital Assets Treasury - Initial cryptocurrency purchases have been made in Bitcoin, Ethereum, Solana, and ResearchCoin, with a focus on multi-chain digital asset growth and DeFi integration [5][6] - A new Crypto Advisory Board has been formed to enhance support for cryptocurrency audit and compliance, with additional members expected to join soon [5][6] - The company has engaged Fireblocks for secure institutional-grade infrastructure and custody technology services for its crypto treasury platform [5][6] Future Outlook - Significant milestones are anticipated in both drug development and digital asset purchases, positioning Silo to capitalize on emerging opportunities [6] - The company plans to pursue additional therapeutic indications for SPC-15 and secure the FDA's 505(b)(2) accelerated regulatory pathway for clinical development [8]